Post has attachment
>RepliCel Life Sciences Announces Completion of the Final Injection in Its Tendon Repair Clinical Trial
Initial Safety and Clinical Efficacy Data from the RCT-01 Trial is Expected to be Available for Analysis in December

#tenniselbow #tendinosis #repetitivestraininjury #rsi #tendinopathy #tendinitis #carpaltunnel #carpaltunnelsyndrome 

Post has attachment
>What they discovered, using mouse models to mimic early tendon damage, was a molecule called interleukin 33 (IL-33), which was functionally and temporally related to type III collagen production.
In other words, neutralizing IL-33 regulated the levels of type III collagen.
In a complicated process involving microRNA delivery vehicles, researchers were able to “switch off” the production of type III collagen and revert back to type I for healthy, strong, and rapid tendon repairs.

http://www.valuebasedcancer.com/vbcr-issues/2015/june-2015-vol-4-no-3/26206-tendinopathy-at-the-molecular-level-a-translational-journey

Post has attachment

Post has attachment
>LAKE FOREST, Calif., March 29, 2016 /PRNewswire/ -- Tenex Health Inc. has obtained FDA 510K clearance for its new TX2 MicroTip.
The TX2 MicroTip will primarily be utilized to address tendinosis of the shoulder and hip, two areas that were more difficult to reach using the original TX1 MicroTip due to its length.

Post has attachment
"CollPlant announces positive results for a clinical trial of rhCollagen (recombinant human collagen) Vergenix STR in the treatment of tennis elbow tendinopathy - CollPlant's rhCollagen is identical to the type I collagen produced by the human body"

>Given that CollPlant's rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response

#tenniselbow #tendinosis #repetitivestraininjury #rsi #tendinopathy #tendinitis #carpaltunnel #carpaltunnelsyndrome 

Post has attachment
>RepliCel Receives European Patent for its Innovative Dermal Injector Technology

RCI-02 injector device promises the potential for unparalleled injection precision, the use of less anesthetic per procedure, and the enhanced treatment of fine wrinkles of the face, décolleté and hands

VANCOUVER, BC – January 11, 2016 – RepliCel Life Sciences Inc.
(OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced that it has been granted a patent (EP2623146) by the European Patent Office for its injection device technologies.

The first device being developed under this patent, RCI-02, is designed for injecting hyaluronic acid as a dermal filler.
The device is also being developed for the injection of RepliCel’s RCH-01 hair restoration and RCS-01 skin rejuvenation products.
Future iterations of the technology and device will be optimized for other injectables such as drugs, vaccines, fat grafts, etc.

“This patent grant is an important milestone for the company as it underpins the commercial value of RCI-02 for the delivery of other injectables beyond our own products.
RCI-02 coupled with an application in the area of hyaluronic acid (HA) represents an early opportunity for licensing and revenue,” stated RepliCel CEO Lee Buckler.

Overall benefits of this next-generation dermal injector technology include improved handling, reduction or elimination of the need for local anesthetic, quicker procedure times, an expectation of more consistent clinical results because of the injector’s controls, and a significant expansion of the areas that can be addressed with dermal fillers due to the ability to conduct broad, shallow, and evenly-dispersed injections.
Additionally, it is expected that a whole new class of injection specialists may be enabled to perform certain dermal injection procedures due to the device’s simplicity and programmability.

“RCI-02 was originally conceived to deliver our cellular products; however, we believe this device will have a profound impact on all dermal injections – particularly in the cosmetic dermal injection market,” commented Dr.
Rolf Hoffmann, RepliCel’s Chief Medical Officer, who is a practicing dermatologist and remains the visionary for the RCI-02 injector.
“Dermatologists have been hindered for years by a single needle syringes’ inability to precisely deliver approved dermal fillers into fine wrinkles of the face, décolleté, and hands.
RCI-02 is designed to address these unserved markets while also improving on current markets by enabling precise and repeatable delivery of injectable substances.
RCI-02 will enable clinicians to better control injection consistency while also enabling less skilled clinicians to undertake these procedures with the desired results.”

“Overall, we expect RCI-02 will increase the market for existing cosmetic injectables by expanding their use into applications not previously addressable, shortening procedure times, and improving both patients’ experience and cosmetic results.
We believe ensuring the optimal and controlled delivery of our cell-based products is an important component to the commercial value we are creating around the development of our products for both aging or sun damaged skin and pattern baldness,” commented Lee Buckler, CEO.

About RCI-02

The RCI-02 injector was designed with input from dermatologists, industrial designers, and electronic and medical device engineers to improve the delivery of a variety of injectables in a controlled, precise manner, removing the risks and uncertainties of injection outcomes currently resulting from manually operated, single-needle syringes.




Post has attachment

Post has attachment
"In the tendinopathic regions, compared to the flanking healthy tissue, we observed
1) an increase in the ratio of collagen III:I proteins,
2) buckling of the collagen fascicles in the extracellular matrix,
3) buckling of tenocytes and their nuclei, and
4) an increase in the ratio small:large diameter collagen fibrils.
In summary, load-induced non-rupture tendinopathy in humans is associated with localized biochemical changes, a shift from large to small diameter fibrils, buckling of the tendon extracellular matrix, and buckling of the cells and their nuclei."
 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981497/

Post has attachment

Post has attachment
Echometrix moves new ultrasound technology from animals to humans – (EchoSoft give quantitative data about mechanical characteristics and properties, like stiffness, and about the status of musculoskeletal (tendon and ligament) tissue)
Wait while more posts are being loaded